华东医药创新皮肤外用制剂罗氟司特乳膏0.05%上市许可申请获NMPA受理

Core Viewpoint - Huadong Medicine's subsidiary has received acceptance for the marketing application of ZORYVE, indicating progress in its product pipeline for treating atopic dermatitis in young children [1] Group 1: Company Developments - Huadong Medicine's wholly-owned subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration (NMPA) for the marketing application of ZORYVE 0.05% [1] - The application is specifically for the indication of local external treatment for mild to moderate atopic dermatitis in patients aged 2 to 5 years [1]